100
Participants
Start Date
September 20, 2016
Primary Completion Date
September 30, 2022
Study Completion Date
March 31, 2024
Injection (2x106 ASC/5ml).
Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
Injection (10x106 ASC/5ml).
Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
Placebo
Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.
UH Montpellier, Montpellier
University Hospital, Toulouse
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
National University of Ireland, Galway, Ireland
OTHER
Istituto Ortopedico Rizzoli
OTHER
Etablissement Français du Sang
OTHER
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
European Clinical Research Infrastructure Network
OTHER
HUMAN MED AG (HM)
UNKNOWN
Stichting Katholieke Universiteit
OTHER
SPORTS SURGERY CLINIC LIMITED
UNKNOWN
University of Padova
OTHER
EVANGELISCHES WALDKRANKENHAUS SPANDAU KRANKENHAUSBETRIEBS GGMBH (EWK)
UNKNOWN
PINTAIL LTD (PT)
UNKNOWN
Centre National de la Recherche Scientifique, France
OTHER
University of Ulm
OTHER
Cambridge University Hospitals NHS Foundation Trust
OTHER
Aries srl (ARIES)
UNKNOWN
University Hospital, Montpellier
OTHER